What to know about the VanEck QUAL ETF
The VanEck QUAL ETF gives investors exposure to large companies from developed countries around the world, excluding Australia.
According to our most recent data, the QUAL ETF had $2831.33 million of money invested. With QUAL’s total funds under management (FUM) figure over $100 million, the ETF meets our team’s minimum investment criteria for FUM levels. As a general rule, our team draws the line at $100 million for ETFs in the International shares sector because we believe that, relative to smaller ETFs, achieving this amount of FUM lowers the chance that the ETF issuer will close the ETF.
Keep learning about the QUAL ETF. Click here to access our free ETF review.
The Fidante Partners Limited XARO ETF – key points
The ActiveX Ardea XARO Fund provides investors with exposure to an actively managed portfolio of fixed income products, particularly government bonds, while implementing risk management strategies that aim to provide protection from interest rate fluctuations and general market volatility.
With our numbers for December 2021, XARO’s FUM stood at $902.15 million. Since the XARO’s FUM is over $100 million, our investing team would say the ETF has met our minimum criteria for the total amount invested, otherwise known as FUM. A very sustainable ETF in the Active ETF (e.g. ETMF) sector should be able to scale well and become profitable for the ETF issuer.
A look at the XARO ETF fee load?
Fidante Partners Limited, the ETF issuer, charges a yearly management fee of 0.5% for the XARO ETF. Meaning, if you invest $2,000 for a full year from now you can expect to pay a management fee of around $10.00.
This management fee is below the average for all ETFs on our Best ETFs Australia list of ETFs. However, you might still be able to find a cheaper ETF for less.
Before rushing out and investing in the XARO fund, consider searching our full ETF list to compare the fees and costs of another ETF side-by-side. Another idea might be using our website to get a free but comprehensive investment review on XARO.